Top Medical News

Ozanimod Shows Long-Term Safety, Efficacy in Open-Label Extension

September 18, 2020

By Marco Meglio

Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.

Sumifilam Improves Multiple Alzheimer Disease Biomarkers in Phase 2b Study

September 17, 2020

By Marco Meglio

The results point to the potential for sumifilam to become a transformative treatment for patients with Alzheimer disease.

Addressing Loneliness and Social Isolation in Patients With Parkinson Disease

September 17, 2020

By Matt Hoffman

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.

Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD

September 17, 2020

By Marco Meglio

Two posters presented at MDS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.

Apomorphine Sublingual Film Shows Long-Term Efficacy in OFF Episode Treatment

September 16, 2020

By Matt Hoffman

The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.

Featured


Latest Videos


Most Recent

THN102 Is Safe, Improves Excessive Daytime Sleepiness in Parkinson Disease

September 16, 2020

The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.

Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MS

September 16, 2020

The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.

Neurology Residency Training During a Pandemic

September 16, 2020

In part 2 of this interview, Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, describes how her resident program experience was impacted by the pandemic.

Amantadine Shows Treatment Durability for Reducing OFF Time in Parkinson Disease

September 15, 2020

The percentage of patients reporting no OFF time and no impact of OFF on daily function more than doubled by the first on-treatment visit in this open-label trial.

Tau Levels May Predict Early Disability, Worse Prognosis in MS

September 15, 2020

Data show that higher CSF tau levels at diagnosis correlated with worse disability independent of age, though no such associations were identified with amyloid-beta.

Levodopa-Carbidopa Intestinal Gel Superior to Immediate Release Capsules for ON Time Without Dyskinesia

September 15, 2020

Benefits of levodopa-carbidopa intestinal gel lasted throughout the day and showed greater benefits of continuous dopaminergic stimulation in disease control than immediate release oral capsules.

Opicapone Improves ON, OFF Time in Levodopa-Treated Patients With Parkinson Disease

September 14, 2020

The COMT inhibitor, which was approved in April 2020, may be a worthwhile option as a first-line adjunctive treatment for those with Parkinson disease with motor fluctuations.

Levodopa-Carbidopa Intestinal Gel Effective for Dyskinesia in Advanced Parkinson Disease

September 14, 2020

Improvement in dyskinesia occurred after 2 weeks of treatment with levodopa-carbidopa intestinal gel and was sustained throughout the study.

Ponesimod Linked to Low Levels of Disease Activity in Relapsing Multiple Sclerosis

September 14, 2020

No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.

NIH Awards Grant to Cleveland Clinic to Establish Alzheimer Disease Research Center

September 14, 2020

The new center is part of the first cohort of centers nationally to receive this new NIH funding and is the first and only in Nevada.

COVID-19 Has Negative Impact on Parkinson Disease Symptom Management

September 13, 2020

Supporting patient activation of their knowledge, skill, and confidence in managing their health may empower patients in times of stress.

Parkinson Disease Gene Therapy VY-AADC01 Proves Safe With Signs of Efficacy

September 13, 2020

Three-year data from a phase 1 study of Voyager Therapeutics’ VY-AADC01 suggest it is safe and offers potential benefits for patients with Parkinson disease.

Bilateral Focused Ultrasound Thalamotomy Safe, Effective in Essential Tremor

September 12, 2020

Scores reflective of tremor in each body part and task performance improved by 71% in patients from baseline before first thalamotomy to 6 months after second thalamotomy.

Directional Deep Brain Stimulation Linked to Wider Therapeutic Window in Parkinson Disease

September 12, 2020

After 3 months of treatment, an overwhelming number of clinicians and patients preferred directional over omnidirectional DBS.

Cannabinoid May Improve Nonmotor Symptoms in Parkinson Disease

September 12, 2020

Results from a phase 2 pilot study of nabilone in Parkinson disease suggest that the synthetic cannabinoid might hold therapeutic potential for nonmotor symptoms.

NeurologyLive Friday 5 — September 11, 2020

September 11, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 11, 2020.

Ofatumumab Highly Effective in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis

September 11, 2020

Treatment-naïve patients showed consistent results with the overall study population that was observed in the ASCLEPIOS I and II trials.

Episode 17: The Metamorphosis of Migraine: Discovery and Development

September 11, 2020

Mind Moments, a podcast from NeurologyLive, brings you an exclusive interview with Stewart Tepper, MD, in part 1 of this special 3-part multimedia series on the evolution of migraine care.

Disability, Economic Burden Greater in MS Patients With High Levels of Fatigue

September 11, 2020

Patients with relapsing multiple sclerosis and high levels of fatigue were less likely to be employed full-time than those with MS with low fatigue.

Portable, Low-Field MRI Equivalent to Conventional Imaging for Brain Injury

September 10, 2020

Point-of-care, 64mT MRI performs as well as conventional CT and MRI while improving patient safety.